First Trust Direct Indexing L.P. Lowers Stake in ICU Medical, Inc. (NASDAQ:ICUI)

First Trust Direct Indexing L.P. trimmed its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 3.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,763 shares of the medical instruments supplier’s stock after selling 66 shares during the period. First Trust Direct Indexing L.P.’s holdings in ICU Medical were worth $321,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ICUI. Allworth Financial LP raised its stake in ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 100 shares during the last quarter. Xponance Inc. raised its stake in shares of ICU Medical by 6.0% during the second quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock worth $235,000 after purchasing an additional 112 shares during the last quarter. CWM LLC lifted its holdings in shares of ICU Medical by 18.5% during the second quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock worth $91,000 after purchasing an additional 120 shares during the period. Hexagon Capital Partners LLC grew its position in ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 122 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 173 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. KeyCorp increased their target price on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Jefferies Financial Group began coverage on ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 price target on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and an average price target of $170.25.

ICU Medical Stock Performance

ICUI opened at $172.00 on Tuesday. ICU Medical, Inc. has a 1-year low of $78.28 and a 1-year high of $188.53. The stock has a market cap of $4.20 billion, a P/E ratio of -58.90 and a beta of 0.66. The stock’s 50 day simple moving average is $174.09 and its 200 day simple moving average is $137.78. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter last year, the business posted $1.58 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, equities analysts anticipate that ICU Medical, Inc. will post 3.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the sale, the vice president now directly owns 4,482 shares in the company, valued at $645,901.02. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Virginia Ruth Sanzone sold 2,050 shares of ICU Medical stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares in the company, valued at $645,901.02. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,973,261.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 52,552 shares of company stock worth $8,741,402. Insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.